399 related articles for article (PubMed ID: 15003653)
21. Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C.
Chapko MK; Yee HS; Monto A; Dominitz JA
Vaccine; 2010 Feb; 28(7):1726-31. PubMed ID: 20044051
[TBL] [Abstract][Full Text] [Related]
22. Cost-benefit analysis of hepatitis a vaccination in Thailand.
Teppakdee A; Tangwitoon A; Khemasuwan D; Tangdhanakanond K; Suramaethakul N; Sriratanaban J; Poovorawan Y
Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):118-27. PubMed ID: 12118439
[TBL] [Abstract][Full Text] [Related]
23. [Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai].
Wu GY; Gong YL; Yu SL; Shao RT; Qin HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):474-8. PubMed ID: 15231120
[TBL] [Abstract][Full Text] [Related]
24. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context.
Sartori AM; de Soárez PC; Novaes HM; Amaku M; de Azevedo RS; Moreira RC; Pereira LM; Ximenes RA; Martelli CM
Vaccine; 2012 Dec; 30(52):7489-97. PubMed ID: 23107593
[TBL] [Abstract][Full Text] [Related]
26. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults.
Van Herck K; Leroux-Roels G; Van Damme P; Srinivasa K; Hoet B
Travel Med Infect Dis; 2007 May; 5(3):171-5. PubMed ID: 17448944
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of hepatitis A vaccination for adults in Belgium.
Luyten J; Van de Sande S; de Schrijver K; Van Damme P; Beutels P
Vaccine; 2012 Sep; 30(42):6070-80. PubMed ID: 22858555
[TBL] [Abstract][Full Text] [Related]
28. [Cost-benefit analysis of vaccinal prevention of hepatitis B policy].
Kerleau M; Flori YA; Nalpas B; Lanoé JL; Berthelot P; Fardeau-Gautier M
Rev Epidemiol Sante Publique; 1995; 43(1):48-60. PubMed ID: 7892516
[TBL] [Abstract][Full Text] [Related]
29. Economic models of hepatitis A virus immunization.
O'Connor JB; Imperiale TF; Singer ME
Hepatology; 1999 Jul; 30(1):343-5. PubMed ID: 10428627
[No Abstract] [Full Text] [Related]
30. Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs.
Deneke MG; Arguedas MR
Expert Rev Vaccines; 2003 Oct; 2(5):661-72. PubMed ID: 14711327
[TBL] [Abstract][Full Text] [Related]
31. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
[TBL] [Abstract][Full Text] [Related]
32. The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule.
Keystone JS; Hershey JH
Int J Infect Dis; 2008 Jan; 12(1):3-11. PubMed ID: 17643334
[TBL] [Abstract][Full Text] [Related]
33. Public Health Impact and Cost-Effectiveness of Hepatitis A Vaccination in the United States: A Disease Transmission Dynamic Modeling Approach.
Dhankhar P; Nwankwo C; Pillsbury M; Lauschke A; Goveia MG; Acosta CJ; Elbasha EH
Value Health; 2015 Jun; 18(4):358-67. PubMed ID: 26091589
[TBL] [Abstract][Full Text] [Related]
34. Implementation of a hepatitis A/B vaccination program using an accelerated schedule among high-risk inmates, Los Angeles County Jail, 2007-2010.
Costumbrado J; Stirland A; Cox G; El-Amin AN; Miranda A; Carter A; Malek M
Vaccine; 2012 Nov; 30(48):6878-82. PubMed ID: 22989688
[TBL] [Abstract][Full Text] [Related]
35. Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine.
Beran J
Expert Rev Vaccines; 2007 Dec; 6(6):891-902. PubMed ID: 18377352
[TBL] [Abstract][Full Text] [Related]
36. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
Vimolket T; Poovorawan Y
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness and cost benefit of viral hepatitis B vaccination in the Slovak Republic.
Hudecková H; Straka S; Szilágyiová M; Avdicová M; Rusnáková S
Cent Eur J Public Health; 2002 Dec; 10(4):146-8. PubMed ID: 12528387
[TBL] [Abstract][Full Text] [Related]
38. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine.
Van Damme P; Van Herck K
Expert Rev Vaccines; 2004 Jun; 3(3):249-67. PubMed ID: 15176942
[TBL] [Abstract][Full Text] [Related]
39. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.
Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP
Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults.
Rosenthal P
Hepatology; 2003 Jan; 37(1):44-51. PubMed ID: 12500187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
